Coexistence of malignant phyllodes tumor and her2-positive locally advanced breast cancer in distinct breasts: A case report  by Sato, Tomoi et al.
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INTRODUCTION:  Phyllodes  tumor  of  the  breast  is  a rare biphasic  neoplasm,  accounting  for less  than  1%  of
all breast  tumors.  Coexistence  of  phyllodes  tumor  and  breast  cancer  in distinct  breasts  is extremely  rare.
CASE  PRESENTATION:  A 47-year-old  Japanese  woman  presented  with bilateral  breast  lumps.  A  HER2-
positive,  unresectable  invasive  carcinoma  in  the  right  breast  and  ﬁbroadenoma  in the  left  were  diagnosed
via  core  needle  biopsy.  During  chemotherapy  with  anti-HER2  therapy,  the  breast  cancer  shrank  quickly,
while  the  left  breast  lump suddenly  enlarged.  Under  a diagnosis  of  malignant  neoplasm  of the  breast,  left
mastectomy  was  performed.  Malignant  phyllodes  tumor  was  diagnosed  by  postoperative  histological
examination  and  recurred  in  multiple  areas  as early  as  2  months  after  surgery.
DISCUSSION:  Only  10 cases  of  coexisting  phyllodes  tumor  and  breast  cancer  in distinct  breasts  have  been
reported  in  the English  literature.  Phyllodes  tumor  associated  with  breast  cancer  in distinct  breasts  tendsrastuzumab
ertuzumab
to  be malignant.  This  is  the  ﬁrst  case  of phyllodes  tumor  rapidly  enlarging  during  anti-HER2  chemotherapy
for  locally  advanced  HER2-positive  breast  cancer.
CONCLUSION:  Even  during  effective  treatment  of  advanced  or recurrent  breast  cancer,  attention  should
also  be  paid  to the  contralateral  breast  for  the possible  association  of  a second  malignancy  such  as
phyllodes  tumor.
©  2016  The  Authors.  Published  by Elsevier  Ltd.  on  behalf  of  IJS Publishing  Group  Ltd.  This is  an  open
he  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).access  article  under  t
. Introduction
Phyllodes tumor of the breast (PT) is a rare biphasic neoplasm
omposed of epithelial and stromal elements, and accounts for less
han 1% of all breast tumors [1]. Although even more uncommon,
reast cancer (BC) can occur associated with PT: inside or outside
f the PT; synchronously or metachronously; in the same breast
r in distinct breasts [2–5]. We  report here an extremely rare case
f the synchronous coexistence of malignant PT and HER2-positive
ocally advanced BC in distinct breasts.
. Case presentation
A 47-year-old Japanese woman, who had no notable past med-
cal and familial history, presented with bilateral breast lumps: a
3 cm mass with skin ulceration in the right breast and a 5.5 cm,
obulated mass with a smooth surface in the left. Mammogram of
he left side revealed a lobulated mass with a smooth surface in the
Abbreviations: PT, phyllodes tumor; BC, breast cancer; FA, ﬁbroadenoma.
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Fig. 1. Mammogram of the left breast. A lobulated mass with a smooth surface could
be  seen. Mammogram of the right breast was  not performed due to the presence of
a  huge mass and skin ulceration.
ttp://dx.doi.org/10.1016/j.ijscr.2015.12.043
210-2612/© 2016 The Authors. Published by Elsevier Ltd. on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (http://
reativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 2. Ultrasonography of the left breast at ﬁrst presentation (A) and after 3 months of anti-HER2 chemotherapy (B). A well-deﬁned, low-echoic mass with a homogeneous
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uggesting intratumoral hemorrhage (B).
pper outer quadrant of the left breast (Fig. 1), but no mammogram
f the right side was performed due to the presence of a huge mass
ith skin ulceration. Ultrasonography of the left breast revealed a
ell-deﬁned, low-echoic mass with a homogeneous intratumoral
choic pattern, suggesting a benign tumor (Fig. 2A). On the right,
here were massive axillary lymph node metastases. HER2-positive
nvasive carcinoma in the right breast and ﬁbroadenoma (FA) rather
han PT in the left were diagnosed by core needle biopsy (Fig. 3).
ecause the BC in the right breast was unresectable, anti-HER2 ther-
py with docetaxel, trastuzumab and pertuzumab was initiated.
fter 3 months, the BC had shrunk markedly and ﬁnally disap-
eared on physical examination and CT, while the mass in the
eft breast enlarged suddenly (Figs. 2 and 4). Repeated core nee-
le biopsy of the left breast revealed a malignant neoplasm, such
s sarcoma, malignant PT or metaplastic carcinoma; therefore, left
astectomy and axillary lymph node sampling were performed. frozen section of the sampled lymph nodes revealed metastases
f adenocarcinoma cells, and left axillary lymphadenectomy was
erformed. The mass was 100 × 90 × 70 mm with massive hemor-
hagic necrosis (Fig. 5). Histologically, the mass was composed of-HER2 chemotherapy, the mass suddenly enlarged and contained ﬂuid, potentially
dense atypical spindled mesenchymal cells with numerous mitoses
(50 mitoses/10 high-power ﬁelds, Fig. 6). Benign PT was also
observed next to the malignant component (Fig. 6), and malignant
PT was diagnosed. The lymph node metastases were poorly dif-
ferentiated adenocarcinoma with positive staining for HER2, and
therefore metastasis from the contralateral BC was  diagnosed. Two
months after the operation, multiple lung and liver metastases
occurred. Computed tomography-guided core needle lung biopsy
revealed PT metastasis. Subsequently, the patient preferred pallia-
tive care rather than cytotoxic chemotherapy. She died 9 months
after the operation.
3. Discussion
Phyllodes tumor is a rare biphasic, ﬁbroepithelial neoplasm,
which is sub-classiﬁed into benign, borderline and malignant types,
based on the following features: degree of stromal cellular atypia,
mitotic activity, presence or absence of stromal overgrowth, and
inﬁltrative or circumscribed tumor margin [1]. Most PTs are benign
CASE  REPORT  –  OPEN  ACCESS
T. Sato et al. / International Journal of Surgery Case Reports 19 (2016) 163–167 165
Fig. 3. Histology of the core needle biopsy from the left breast tumor. Fibroadenoma rather than phyllodes tumor was  diagnosed due to the absence of a leaf-like pattern,
stromal overgrowth or mitosis.
Fig. 4. Computed tomography before chemotherapy and anti-HER2 therapy (A) and
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b months after the therapy (B). The right BC had shrunk markedly, but the left breast
umor had enlarged rapidly. Enhanced medium was  not used due to allergic reaction.
r borderline, and malignant PT is even less common, accounting
or less than 30% [6,7].
Although extremely rare, BC, either invasive or non-invasive,
an be associated with PT: inside or outside of the PT; syn-
hronously or metachronously; in the ipsilateral or other breast.
bdul Aziz et al. summarized 39 cases of the coexistence of PT
nd BC in 2010 [2], among which, coexisting PT and BC in distinct
reasts occurred in only 7 cases and was even less common than
eing inside the PT (21 cases) or in the ipsilateral breast (16 cases;
 cases were duplicated). Subsequently, we found three additional
ases of the synchronous coexistence of PT and BC in distinct breasts
3–5]. Thus, overall only 10 cases have been reported in the English
iterature so far, and the current case is therefore extremely rare.
ll 11 cases of coexisting PT and BC in distinct breasts, including
he current case, are summarized in the Table 1. Phyllodes tumor
f the breast associated with BC in the contralateral breast tends to
e malignant. Most previously reported cases had favorable prog-
oses, while only two patients, including the current case, had
ecurrence of PT and died.The etiology of the association between BC and PT is unknown.
enetic changes with intratumoral genetic heterogeneity have
een reported [8] and might lead to malignant transformation ofFig. 5. Macroscopic ﬁndings of the resected left breast tumor. The mass was
100 × 90 × 70 mm with massive hemorrhagic necrosis.
epithelial as well as stromal components, resulting in the develop-
ment of benign to malignant PT and the association of BC inside the
PT. However, their association in distinct breasts has not yet been
explained. We  speculate that this association was  coincidental, as
discussed by other authors [4].
In the current case, PT rapidly progressed during chemother-
apy with taxane and anti-HER2 therapy. This treatment might
have induced malignant transformation and accelerated its growth;
however, there is no report of PT rapidly progressing during such
treatment, and thus it might have been coincidental. Taxane can be
used to treat various sarcomas [9], and therefore it is possible that
the treatment might have affected part of the PT, resulting in necro-
sis and intratumoral hemorrhage, and ﬁnally, rapid enlargement of
the tumor.
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Fig. 6. Histology of the left breast tumor. A, Panoramic view shows benign, borderline and malignant parts of PT and their transition (arrowhead). B, Magniﬁed view of the
benign  part of the PT. C, Magniﬁed view of the malignant part of the PT. Dense atypical spindled mesenchymal cells with numerous mitoses (50 mitoses/10 high-power
ﬁelds) can be seen.
Table 1
Reported cases of coexisting phyllodes tumor and breast cancer in distinct breasts.
No Author Year Age PT PT size (mm) Timing BC Outcome
1 McCormick [3] 1977 45 Malignant 150 Synchronous IDC 8 M alive
2  Stone-Tolin 1982 59 Benign 220 Metachronous IDC 15 M alive
3  Morimoto 1993 49 Malignant 110 Synchronous LCIS 132 M alive
4  Powell 1994 NS Malignant NS Synchronous LCIS NS
5  Powell 1994 NS Malignant NS Metachronous IDC Dead due to BC
6  Kasami 1997 47 Malignant 90 Synchronous ILC 17 M dead due to PT
7  Gebrim 2000 58 Malignant 300 Synchronous ILC 84 M alive
8  Merch 2006 NS Malignant 50 Synchronous IDC 32 M alive
9
1
5
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d9  Neto [4] 2012 66 Benign 
10  Jain [5] 2014 43 Borderline 
11  Current case 2015 47 Malignant 
Malignant PT rarely metastasizes to lymph nodes, and axillary
ymphadenectomy should normally be avoided [1]. In the current
ase, preoperative diagnosis of the left breast mass could have been
etaplastic carcinoma and an intraoperative frozen section of the
ampled lymph node in the left axilla revealed involved cancer cells,
esulting in unnecessary lymphadenectomy. We  did not expect
ymph node metastases from the contralateral BC which clinically
isappeared after standard anti-HER2 chemotherapy.0 Synchronous IDC NS
50 Synchronous IDC 6 M alive
5 Synchronous IDC 9 M dead due to PT
Preoperative diagnosis of PT via imaging modalities and nee-
dle biopsies is often difﬁcult. Using both modalities, differentiating
between benign PT and FA is frequently challenging due to their
morphological similarities [1,7,10]. Ward et al. reported that the
sensitivity of core needle biopsy in diagnosing PT was  63% and
imaging was 65% [7]; however, it was much lower for benign PT
than for borderline or malignant PT [7]. In addition, intratumoral
heterogeneity can exist, and therefore complete surgical excision is
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sually required for ﬁnal assessment to discriminate from FA [1]. In
he current case, FA was initially diagnosed via core needle biopsy,
robably because the tissue sampled was only from the benign part
here signiﬁcant cellularity or mitosis was absent.
Because large size is the one of the signiﬁcant clinical ﬁndings
uggesting PT rather than FA [10], the mass in the left breast should
ave been excised to conﬁrm the histology at the ﬁrst presentation
n the current case. Surgical removal is the mainstay of PT treat-
ent and usually leads to a favorable prognosis [6]. However, in
he current case, the presence of unresectable, locally advanced BC
n the contralateral breast precluded removal of the left breast mass
ntil it had become massive, resulting in a negative outcome.
. Conclusion
Here we report an extremely rare case of the coexistence of
ocally advanced BC and malignant PT in distinct breasts. Only 10
ases of coexisting PT and BC in distinct breasts had been reported
o far in the English literature. Phyllodes tumor which associates
ith BC in the contralateral breast is tend to be malignant. Even
ith a case of advanced or recurrent BC and during effective treat-
ent, careful attention should also be paid to the contralateral
reast for the possible association of a second malignancy such as
T.
onﬂicts of interest
I have no conﬂicts of interest.
unding
There are no sources of funding.
thical approval
This is not a research study.
onsent
Written informed consent was obtained from the patient for the
ublication of this case report and accompanying images. A copy
f the written consent is available for review by the Editor-in-Chief
f this journal.ompeting interests
The authors declare that they have no competing interests.
pen Access
his article is published Open Access at sciencedirect.com. It is distrib
ermits unrestricted non commercial use, distribution, and reproduct
redited.PEN  ACCESS
ery Case Reports 19 (2016) 163–167 167
Authors’ contributions
TS was the physician in charge of this patient and made
treatment decisions. IM participated in the operation and the man-
agement of this patient. TS was the pathologist responsible for
the macroscopic and microscopic ﬁndings. All authors read and
approved the ﬁnal manuscript.
Guarantor
This is not a research study. All authors read and approved
the ﬁnal manuscript. Therefore, all authors are responsible for this
report.
References
[1] B.O. Anderson, T.J. Lawton, C.D. Lehman, R.E. Moe, Phyllodes tumor, in: J.R.
Harris, M.E. Lippman, M.  Morrow, C.K. Osborne (Eds.), Diseases of the Breast,
3rd edition, Lippincott Williams & Wilkins, Philadelphia, 2004, pp. 991–1006.
[2] M.  Abdul Aziz, F. Sullivan, M.J. Kerin, G. Callary, Malignant phyllodes tumour
with liposarcomatous differentiation, invasive tubular carcinoma, and ductal
and lobular carcinoma in situ: case report and review of the literature, Pathol.
Res. Int. (2010), http://dx.doi.org/10.4061/2010/501274.
[3] M.V. McCormick, S.P. Pillay, Malignant cystosarcoma phyllodes associated
with scirrhous carcinoma of the breast. A case report, South Afr. Med. J. 52
(1977) 893–894.
[4] G.B. Neto, C. Rossetti, N.A. Souza, L.A. Fonseca F, L.A. Azzalis, V.B. Junqueira,
V.E.  Valenti, L.C. de Abreu, Coexistence of benign phyllodes tumor and
invasive ductal carcinoma in distinct breasts: case report, Eur. J. Med. Res. 17
(2012) 8, http://dx.doi.org/10.1186/2047-783x-17-8.
[5] S. Jain, R. Kaur, R. Agarwal, P. Chopra, Bilateral invasive duct carcinoma,
phyllodes tumor and multiple ﬁbroadenomas of breast associated with lymph
node metastases-rare coexistence, Indian J. Surg. Oncol. 5 (2014) 186–188.
[6] A.W. Chaney, A. Pollack, M.D. McNeese, G.K. Zagars, P.W. Pisters, R.E. Pollock,
K.K. Hunt, Primary treatment of cystosarcoma phyllodes of the breast, Cancer
89  (2000) 1502–1511.
[7] S.T. Ward, A.J. Jewkes, B.G. Jones, S. Chaudhri, R.K. Hejmadi, T. Ismail, M.T.
Hallissey, The sensitivity of needle core biopsy in combination with other
investigations for the diagnosis of phyllodes tumours of the breast, Int. J. Surg.
10 (2012) 527–531.
[8] A.M. Jones, R. Mitter, R. Springall, T. Graham, E. Winter, C. Gillett, A.M. Hanby,
I.P.  Tomlinson, E.J. Sawyer, A comprehensive genetic proﬁle of phyllodes
tumours of the breast detects important mutations, intra-tumoral genetic
heterogeneity and new genetic changes on recurrence, J. Pathol. 214 (2008)
533–544.
[9] W.J. Kostler, T. Brodowicz, Y. Attems, M.  Hejna, S. Tomek, G. Amann, W.C.
Fiebiger, C. Wiltschke, M.  Krainer, C.C. Zielinski, Docetaxel as rescue
medication in anthracycline- and ifosfamide-resistant locally advanced or
metastatic soft tissue sarcoma: results of phase II trial, Ann. Oncol. 12 (2001)
1281–1288.
10] D.J. Gould, J.A. Salmans, B.K. Lassinger, A. Contreras, C. Gutierrez, E. Bonefas,
K.R. Liscum, E.J. Silberfein, Factors associated with phyllodes tumor of the
breast after core needle biopsy identiﬁes ﬁbroepithelial neoplasm, J. Surg. Res.
178  (2012) 299–303.uted under the IJSCR Supplemental terms and conditions, which
ion in any medium, provided the original authors and source are
